Safety of enzalutamide in patients with metastatic castration‐resistant prostate cancer previously treated with docetaxel: Expanded access in North America

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0045|75|8|836-844

ISSN： 0270-4137

Source： THE PROSTATE, Vol.75, Iss.8, 2015-06, pp. : 836-844

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration‐resistant prostate cancer who progress after docetaxel and abiraterone treatment

By  

CANCER, Vol. 120, Iss. 7, 2014-04 ,pp. : 968-975

John Wiley & Sons Inc

Access to resources Recommend Favorite

Final quality of life and safety data for patients with metastatic castration‐resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279)

By  

BJU INTERNATIONAL, Vol. 116, Iss. 6, 2015-12 ,pp. : 880-887

John Wiley & Sons Inc

Access to resources Recommend Favorite

Optimal sequencing of docetaxel and abiraterone in men with metastatic castration‐resistant prostate cancer

By  

THE PROSTATE, Vol. 270-4137, Iss. 15, 2015-11 ,pp. : 1814-1820

John Wiley & Sons Inc

Access to resources Recommend Favorite

Optimal sequencing of docetaxel and abiraterone in men with metastatic castration‐resistant prostate cancer

By  

THE PROSTATE, Vol. 75, Iss. 15, 2015-11 ,pp. : 1814-1820

John Wiley & Sons Inc

Access to resources Recommend Favorite

Docetaxel rechallenge after an initial good response in patients with metastatic castration‐resistant prostate cancer

By  

BJU INTERNATIONAL, Vol. 115, Iss. 5, 2015-05 ,pp. : 744-752

John Wiley & Sons Inc

Access to resources Recommend Favorite